We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Has Concentra Group Holdings Parent, Inc. (CON) Outpaced Other Medical Stocks This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Concentra Group (CON - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Concentra Group is one of 1009 individual stocks in the Medical sector. Collectively, these companies sit at #3 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Concentra Group is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for CON's full-year earnings has moved 5.4% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the latest available data, CON has gained about 15.8% so far this year. In comparison, Medical companies have returned an average of 6.3%. This means that Concentra Group is performing better than its sector in terms of year-to-date returns.
Another Medical stock, which has outperformed the sector so far this year, is Cencora (COR - Free Report) . The stock has returned 11.6% year-to-date.
For Cencora, the consensus EPS estimate for the current year has increased 3% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Concentra Group is a member of the Medical Services industry, which includes 59 individual companies and currently sits at #84 in the Zacks Industry Rank. This group has gained an average of 4.3% so far this year, so CON is performing better in this area. Cencora is also part of the same industry.
Concentra Group and Cencora could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Has Concentra Group Holdings Parent, Inc. (CON) Outpaced Other Medical Stocks This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Concentra Group (CON - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Concentra Group is one of 1009 individual stocks in the Medical sector. Collectively, these companies sit at #3 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Concentra Group is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for CON's full-year earnings has moved 5.4% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the latest available data, CON has gained about 15.8% so far this year. In comparison, Medical companies have returned an average of 6.3%. This means that Concentra Group is performing better than its sector in terms of year-to-date returns.
Another Medical stock, which has outperformed the sector so far this year, is Cencora (COR - Free Report) . The stock has returned 11.6% year-to-date.
For Cencora, the consensus EPS estimate for the current year has increased 3% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Concentra Group is a member of the Medical Services industry, which includes 59 individual companies and currently sits at #84 in the Zacks Industry Rank. This group has gained an average of 4.3% so far this year, so CON is performing better in this area. Cencora is also part of the same industry.
Concentra Group and Cencora could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.